Welcome to the e-CCO Library!

P451: Evaluating drug sustainability, efficacy and safety of biologic agents in elderly patients with Inflammatory Bowel Disease: a single center retrospective study
Year: 2022
Source: ECCO'22
Authors: Golovics, P.(1);LeBlanc, J.F.(2);Drügg Hahn, G.(1);Wetwittayakhlang, P.(1);Qatomah, A.(1);Wang, A.(1);Boodaghians, L.(1);Liu, J.(3); Al Ali, M.(1);Wild, G.E.(1);Afif, W.(1);Bitton, A.(1);Lakatos, P.L.(1);Bessissow, T.(1);
Created: Friday, 11 February 2022, 3:52 PM
P451: Long-term surgical outcome of ileal pouch-anal anastomosis when used for well-defined Crohn’s disease
Year: 2018
Source: ECCO '18 Vienna
Authors:

D. Mandel, K. Zaghiyan, P. Fleshner*

Created: Thursday, 21 February 2019, 9:14 AM
P451: Safety and efficacy of ferric carboxymaltose (FCM) for the treatment of iron deficiency anaemia in paediatric patients affected by inflammatory bowel disease (pIBD)
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

L. Cococcioni*1, A. Elzein1, S. Sider1, S. Chadokufa1, R. Buckingham1, A. Ocholi1, N. Shah1, S. McCartney2, E. Saliakellis1, O. Borrelli1, F. Kiparissi1

Created: Friday, 22 February 2019, 9:41 AM
P451: The efficacy of infliximab in tacrolomus non-responder with ulcerative colitis
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

T. Miyazaki*, N. Hida, T. Sato, M. Kawai, K. Kamikozuru, T. Takagawa, Y. Yokoyama, M. Iimuro, K. Hori, S. Nakamura

Created: Friday, 22 February 2019, 9:49 AM
P452 Biologic use patterns and predictors for non-persistence and switching of biologics in patients with inflammatory bowel disease: a nationwide population-based study
Year: 2020
Source:

ECCO'20 Vienna

Authors:

Y.S. Jung Prof. Dr.1, M. Han2, S. Park3, J.H. Cheon4

Created: Thursday, 30 January 2020, 10:12 AM
P452: Fecal Microbiota Transplantation Leads to Lower IBD Related Complications in Hospitalized Inflammatory Bowel Disease Patients with Clostridioides difficile Infection: A retrospective cohort study
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Le, P.H.(1)*;Chiu, C.H.(2);Chiu, C.T.(1);Kuo, C.J.(1);Yeh, P.J.(3);Chen, C.C.(3);Pan, Y.B.(4);
Created: Friday, 14 July 2023, 11:05 AM
P452: Impact of implementing a rapid access clinic in a high-volume inflammatory bowel disease centre: accessibility, resource utilisation and outcomes
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

J. Reinglas*1, S. Nene1, L. Gonczi2, Z. Kurti2, S. Restellini3, R. Kohen1, W. Afif1, T. Bessissow1, G. Wild1, E. Seidman1, A. Bitton1, P. Lakatos1

Created: Friday, 22 February 2019, 9:41 AM
P452: Medium to long-term outcomes in patients receiving accelerated dose infliximab induction for acute severe ulcerative colitis (ASUC) in a multi-centre cohort
Year: 2018
Source: ECCO '18 Vienna
Authors:

D. Gibson1, M. McNally2*, J. Doherty1, A. Keogh2, D. Keegan1, K. Byrne1, U. Kennedy3, H. Mulcahy1, S. McKiernan3, F. MacCarthy3, L. Egan2,4, G. Cullen1,4, J. Sheridan1, S. Sengupta4,5, E. Slattery2,4, D. Kevans3,4, G. Doherty1,4

Created: Thursday, 21 February 2019, 9:14 AM
P452: Oral ciclosporin is a convenient, effective and safe rescue therapy in steroid refractory Acute Severe Ulcerative Colitis: A single tertiary centre experience
Year: 2021
Source: ECCO'21 Virtual
Authors: Jiang, C.D.(1);Thalagala, T.(1);Rosembert, D.(2);Parkes, M.(1);Lee, J.(1);Raine, T.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P452: Safety and efficacy of infliximab biosimilar (Remsima©) in Crohn’s disease patients in clinical practice: results after 6 months of treatment
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

M. F. Guerra Veloz*1, F. Argüelles Arias1, R. Perea Amarillo1, L. Castro Laria1, M. B. Maldonado Pérez1, A. Benítez Roldán1, V. Merino2, G. Ramirez2, A. Vilches Arenas3, A. Caunedo Álvarez1

Created: Friday, 22 February 2019, 9:49 AM
P452: Silent anaemia predicts treatment change in patients with Crohn's disease in clinical remission
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Soufleris K., Kafalis N., Katsoula A., Chatzinakos G., Grammatikos N., Giouleme O.

Created: Wednesday, 20 February 2019, 10:36 AM
P452: Tofacitinib Effectiveness and Safety as Therapy for Ulcerative Colitis
Year: 2022
Source: ECCO'22
Authors: McNally, M.(1);Keating, E.(2);Gray, E.(1);McCormick, E.(1);Carroll, A.(3);Palmer, C.(4);Kennedy, U.(1);McKiernan, S.(1);MacCarthy, F.(1);Dunne, C.(1);Hartery, K.(1);Egan, L.(2);Slattery, E.(2);Ryan, B.(3);McNamara, D.(3);O'Connor, A.(3);Breslin, N.(3);O'Donnell, S.(3);Cullen, G.(4);Mulcahy, H.(4);Sheridan, J.(4);Doherty, G.(4);Kevans, D.(1);
Created: Friday, 11 February 2022, 3:52 PM
P453 Comparison of therapeutic effects between groups of thiopurine alone and combination of thiopurine with 5-ASA after remission introduced by oral tacrolimus for patients with severe ulcerative colitis
Year: 2020
Source:

ECCO'20 Vienna

Authors:

T. Sato1, K. Kojima2, R. Koshiba2, K. Fujimoto2, M. Kawai2, K. Kamikoduru2, Y. Yokoyama2, T. Miyazaki2, K. Watanabe1, N. Hida2, S. Nakamura2

Created: Thursday, 30 January 2020, 10:12 AM
P453: Efficacy of therapeutic drug monitoring of anti-TNF therapy in the control of patients with inflammatory bowel disease
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Bernardo S., Fernandes S., Gonçalves A.R., Baldaia C., Valente A., Moura Santos P., Correia L., Velosa J.

Created: Wednesday, 20 February 2019, 10:36 AM
P453: Golimumab in real-world practice in patients with ulcerative colitis: 2-year interim results from a non-interventional trial in Germany
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

N. Teich1, H. Gruemmer2, E. Joergensen3, T. Liceni4, W. Holtkamp-Endemann5, F. Cornillie6, S. Hohenberger7, T. Fischer*7

Created: Friday, 22 February 2019, 9:41 AM
P453: Insufficient vaccination and inadequate immunisation rates amongst Korean patients with inflammatory bowel diseases
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

H. H. Ryu1, H.-S. Lee2, B. D. Ye*3, N. Y. Kim4, E. J. Youn3, J. Y. Park3, E. Kang3, S. W. Hwang1, S. H. Park3, D.-H. Yang1, K.-J. Kim3, J.-S. Byeon1, S.-J. Myung1, S.-K. Yang3

Created: Friday, 22 February 2019, 9:49 AM
P453: Pre-operative vedolizumab treatment and postoperative complications in patients with inflammatory bowel disease: A systematic review and meta-analysis
Year: 2018
Source: ECCO '18 Vienna
Authors:

C. Law1, A. Narula2, A. Lightner3, J.-F. Colombel4, N.P. McKenna5, N. Narula2*

Created: Thursday, 21 February 2019, 9:14 AM
P453: The significance of the concentration of antibodies to infliximab on the frequency of loss of response when alternating the original drug infliximab and its biosimilar in patients with ulcerative colitis.
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Zviaglova, M.(1)*;Knyazev, O.(1);Kagramanova, A.(1);Lischinskaya, A.(1);Podolskaya, D.(2);Nanaeva, B.(2);
Created: Friday, 14 July 2023, 11:05 AM
P453: The use of immunosuppresants is associated with high treatment persistence rates for infliximab and adalimumab as first or second line anti-TNF therapy in patients with inflammatory bowel disease
Year: 2021
Source: ECCO'21 Virtual
Authors: Theodoraki, E.(1);Orfanoudaki, E.(1);Foteinogiannopoulou, K.(1);Drygiannakis, I.(1);Koutroubakis, I.E.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P453: Underutilisation of novel and alternative oral iron preparations may incur unnecessary cost in iron deficiency anaemia treatment in inflammatory bowel disease
Year: 2022
Source: ECCO'22
Authors: Sharma, E.(1);Kotecha, J.(1);Akintimehin, A.(2);Ray, S.(1);Anderson, S.H.(1);Mawdsley, J.(1);Irving, P.M.(1);Samaan, M.A.(1);
Created: Friday, 11 February 2022, 3:52 PM